Holen Sie sich die Stockscreener-App
220.08
1.81%
-4.05
Handel nachbörslich:
220.91
0.83
+0.38%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
AbbVie stock slips after $1.3 billion R&D charge and Revolution Medicines rumor — what investors watch next - TechStock²
J&J Joins Trump Administration’s MFN Pricing Initiative - Citeline News & Insights
Revolution Medicines Soars Amid AbbVie Acquisition Talks - StocksToTrade
What Catalysts Could Shift AbbVie’s Story As Analysts Rework Targets And Drug Expectations - Yahoo Finance
AbbVie Expands Bid to Block Qulipta Copies With Two Patent Suits - Bloomberg Law News
Revolution Medicines Stock Drops After-Hours On AbbVie Denying Acquisition Talks - Stocktwits
AbbVie stock slips on $1.3B charge, deal-rumor denial — what’s next for ABBV - TechStock²
AbbVie Inc. Bets Big on Immunology and Oncology: How Its Drug Portfolio Became the Real Flagship Pro - AD HOC NEWS
Revolution Medicines Stock Jumps. Takeover Buzz Grows, Another Suitor Emerges. - Barron's
Here's What We Expect From AbbVie's Immunology Segment in Q4 - The Globe and Mail
Merck in Talks to Buy Biotech Revolution Medicines, FT Says - Bloomberg.com
Revolution Medicines Stock Soars. Takeover Buzz Grows, Another Suitor Emerges. - Barron's
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight - Benzinga
Revolution Medicines jumps on report AbbVie nears takeover - MSN
AbbVie Inc.: How a Pharma Powerhouse Is Re?Engineering Its Future Beyond Humira - AD HOC NEWS
AbbVie Sues Over Bids To Market Generic Migraine Drugs - Law360
Merck in Deal Talks With Biotech Revolution Medicines, FT Says - Bloomberg.com
Key facts: AbbVie revises EPS guidance; negotiates $20B acquisition - TradingView — Track All Markets
AbbVie stock drops after Revolution deal denial, $1.3 billion charge spooks traders - TechStock²
AbbVie Stock Drops After Guidance Update, Wolfe Downgrade And Deal Denial - Benzinga
AbbVie: The Dividend Does Not Lie (NYSE:ABBV) - Seeking Alpha
AbbVie (ABBV) Warns of Q4 Earnings Impact Due to $1.3B Charge - GuruFocus
AbbVie sees negative Q4 EPS impact from IPR&D expenses - MSN
Merck rises as Wolfe upgrades to Outperform; AbbVie downgraded - Seeking Alpha
AbbVie says it’s not in talks to buy Revolution Medicines; WSJ reports another suitor may prevail - Sherwood News
AbbVie Flags $1.3B Charge, Cuts Fourth-Quarter EPS Outlook - Yahoo Finance
AbbVie, Revolution Medicines Stocks Fall After Drugmaker Denies Takeover Report - Barron's
Aug Big Picture: Can AbbVie Inc. stock continue upward trendDividend Hike & Accurate Trade Setup Notifications - ulpravda.ru
Lockheed, Northrop, Alphabet, Revolution Medicines, AbbVie, Costco, and More Movers - Barron's
Merck upgraded on post-Keytruda growth, AbbVie cut as upside baked inWolfe - Investing.com India
AbbVie (ABBV) Stock Falls After Company Denies Revolution Medicines Buyout Talks - Blockonomi
AbbVie denies it’s in talks to buy Revolution Medicines. Both stocks are falling. - MSN
Northrop, Lockheed, Alphabet, Revolution Medicines, AbbVie, Costco, and More Movers - Barron's
AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73 - simplywall.st
Should Health Canada’s Eight-Week MAVIRET Approval Shape AbbVie’s (ABBV) Post-Humira Growth Story? - Yahoo Finance
AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down - TechStock²
Revolution Medicines dips after AbbVie denies takeover talks - TradingView — Track All Markets
AbbVie (ABBV) Stock Drops as Company Denies Revolution Medicines Acquisition Reports - CoinCentral
AbbVie Lowers Q4, 2025 Adjusted EPS Guidance - MarketScreener
Why Revolution Medicines Shares Are Sliding After Hours On Wednesday - Benzinga
Humira Market to Witness Remarkable Growth With AbbVie Inc., Amgen Inc., Samsung Bioepis - openPR.com
AbbVie (ABBV) Projects Q4 Earnings Impact from $1.3 Billion Char - GuruFocus
AbbVie (ABBV) Receives a Buy from Berenberg Bank - The Globe and Mail
AbbVie flags $1.3B IPR&D charge, warns of Q4 earnings pressure (ABBV:NYSE) - Seeking Alpha
Revolution Medicines Stock Pre-Market (-6.0%): AbbVie Denies Acquisition Talks - Trefis
AbbVie Denies Media Reports of Talks to Buy Revolution Medicines - MarketScreener
What's Happening With Cancer Biotech Erasca Shares This Thursday? - Bitget
AbbVie denies media reports of talks to buy Revolution Medicines - WTVB
Exclusive | Revolution Medicines Draws Takeover Interest - The Wall Street Journal
Stock Movers: Jeffries, AbbVie, Raytheon - Bloomberg.com
AbbVie2025 adjusted EPS guidance range $9.90$9.94SEC filing - MarketScreener
Revolution Medicines (RVMD) Shares Plunge After AbbVie Denies Acquisition Talks - GuruFocus
Abbvie denies WSJ report of talks to buy biotech player Revolutions Medicine - Crain's Chicago Business
AbbVie (ABBV) Denies Acquisition Talks with Revolution Medicines - GuruFocus
AbbVie (ABBV) Denies Discussions with Revolution Medicines - GuruFocus
AbbVie Says It’s Not in Talks to Buy Revolution Medicines - Bloomberg.com
AbbVie says not in talks to buy Revolution Medicinesreport - MSN
AbbVie reports $1.3 billion Q4 expense from acquired research deals - StreetInsider
Revolution Medicines (RVMD) Surges on AbbVie Acquisition Talks - GuruFocus
AbbVie (ABBV) Nears Acquisition Deal with Revolution Medicines - GuruFocus
Erasca up 66% after WSJ report on AbbVie interest in Revolution Medicines - TipRanks
AbbVie M&A Buzz Sends Revolution Medicines RVMD Above $100, ABBV Stock $230+ - FXLeaders
AbbVie (ABBV) Nears Acquisition of Cancer-Drug Firm Revolution M - GuruFocus
AbbVie (ABBV) Nears Acquisition of Revolution Medicines in a Maj - GuruFocus
American pharmaceutical giant in advanced negotiations for a major acquisition - medwatch.com
Exclusive | AbbVie Near Deal for Revolution MedicinesWSJ - The Wall Street Journal
AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition - MarketScreener
0.66%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):